
    
      Patients with ankylosing spondylitis or axial spondyloarthritis who fulfills the inclusion
      and exclusion criteria will be randomized into one of the four arms after an initial one week
      washout period, including: 1) indomethacin 75mg every 12 hours (Q12H); 2) diclofenac 75mg
      Q12H; 3) meloxicam 7.5mg Q12H; 4) celecoxib 200mg Q12H. The treatment length will be 6 weeks.
      Primary outcome is the change of pain score from baseline to week 4 and to week 6.
    
  